NASDAQ · Biotechnology

Immuron Limited (IMRN) Stock

$1.13 -7.38% NASDAQ: IMRN Healthcare

Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products.

Valuation

MetricValue
Price$1.13
Market Cap$7.28M
P/E Ratio-2.03
P/B Ratio0.80
P/S Ratio1.31
EPS (TTM)$-0.90
52-Week High$2.39
52-Week Low$0.68
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-43.95%
ROA-30.69%
ROCE-38.50%
Gross Margin63.69%
Operating Margin-68.38%
Net Margin-62.14%
Debt/Equity0.00
Current Ratio8.04

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$1.0M$2.0M$5.0M$7.0M
Operating Profit$-8.0M$-3.0M$-4.0M$-6.0M$-5.0M
Net Profit$-8.0M$-3.0M$-4.0M$-7.0M$-5.0M
EPS$-1.52$-0.50$-0.66$-1.22$-0.90
Op Margin-5748.5%-375.1%-197.8%-118.3%-73.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$27.0M$25.0M$22.0M$16.0M$10.0M
Total Liabilities$1.0M$2.0M$2.0M$3.0M$2.0M
Cash$25.0M$22.0M$17.0M$12.0M$3.0M
Borrowings$0$0$0$0$0

Latest News

Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar GlobeNewswire · Jul 20, 2026 Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year GlobeNewswire · Jul 16, 2026 Immuron Seeking Partner to Advance IMM-529 in Clostridioides Difficile Infection MT Newswires · Jul 6, 2026 Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy GlobeNewswire · Jul 6, 2026 Presenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live stream GlobeNewswire · May 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-3.0M$-3.0M$-2.0M$-6.0M$-6.0M
Investing Cash Flow$0$0$-3.0M$0$-3.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$22.0M$-3.0M$-5.0M$-6.0M$-9.0M
Free Cash Flow$-3.0M$-3.0M$-2.0M$-6.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.04
EV / EBITDA0.04
FCF Yield-47.19%
Quick Ratio6.83
Interest Coverage-518.14
Return 1Y-33.53%
Return 3Y-44.61%
Return 5Y-76.70%

Ownership

Insiders Held0.00%
Institutions Held1.05%
Institutions Float Held1.05%
Institutional HolderSharesReport Date
Morgan Stanley30,5742026-03-31
Xtx Topco Ltd17,3832026-03-31
Citadel Advisors Llc13,8042026-03-31
Two Sigma Securities, LLC10,9062026-03-31
Rhumbline Advisers7,3672026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
APM $0.81 -0.78% -4.42 $5.15M 0.00%
BOLT $3.95 -0.50% -0.26 $7.59M 0.00%
BRTX $0.20 -2.11% -0.33 $1.83M 0.00%
CLRB $2.37 -2.07% -0.38 $7.57M 0.00%
COCP $0.92 +0.14% -1.46 $12.68M 0.00%

About Immuron Limited

Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.

Immuron Limited is headquartered in AU.

Immuron Limited (IMRN) stock trades at $1.13 with a market capitalization of $7.28M. The stock is valued at a price-to-earnings (P/E) ratio of -2.03, price-to-book of 0.80, price-to-sales of 1.31. Over the past 52 weeks the stock has ranged between $0.68 and $2.39, and currently trades 52.7% below its 52-week high.

On profitability, Immuron Limited generates a return on equity (ROE) of -43.95%, return on capital employed of -38.50%, an operating margin of -68.38%, a net profit margin of -62.14%.

Official website: www.immuron.com.au

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides